Convert Pharmaceuticals, a pioneering Belgian biotech company, has announced the successful initiation of its Phase I-IIa clinical trial for CP-506, a novel hypoxia-activated prodrug, marking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback